Brought to you by 
Valeant pays €314mm in cash for AB Sanitas
May 2011
Executive Summary
Keeping in line with its goal to acquire five ex-US companies before the end of 2011, Valeant Pharmaceuticals International Inc. (neurology and dermatology therapies) has agreed to buy publicly traded Lithuanian generic drug maker AB Sanitas for €314mm ($442mm) in cash and it will assume €50mm in debt.
Deal Industry
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com